Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Histiocytoma, Malignant Fibrous × Epirubicin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 2 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, T-Cell, Peripheral 1 Inflammatory Breast Neoplasms 1 HR+/HER2- Breast Cancer 1 Epstein-Barr Virus Infections 1 Congenital Abnormalities 1 Carcinoma, Adenoid Cystic 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

pembrolizumab 4 Specimen Handling 3 Doxorubicin 3 Radiotherapy 2 Radiation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 CTLA-4 Antigen 2 Biopsy 2 tremelimumab 1 talimogene laherparepvec 1 regorafenib 1 pazopanib 1 olaratumab 1 futibatinib 1 fludarabine 1 eribulin 1 durvalumab 1 cabozantinib 1 avelumab 1 aldesleukin 1 X-Rays 1 Trabectedin 1 Standard of Care 1 Quality of Life 1 Immune Checkpoint Inhibitors 1 Ifosfamide 1 Histamine H2 Antagonists 1 Famotidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡